The pharmacological inhibition of CCR2 with CVC has recently been used for the clinical treatment of NASH.25 However, the beneficial effects of CVC on human fibrosis were questioned in a recent phase III clinical trial.29 Investigations that explore the cellular and molecular mechanisms of CVC in liver fibrosis may help to explain the controversial clinical and experimental data. The gene discussed is CCR2; the disease is Hepatic fibrosis.